RCT OF PREVENTION OF ACCELERATED ATHEROSCLEROSIS IN SLE

描述(取自申请表)： 系统性红斑狼疮(SLE)影响着20多万美国人。一直以来 众所周知，20多年来，系统性红斑狼疮患者患上 加速动脉粥样硬化。已知的危险因素(吸烟、肥胖、家庭 冠心病病史，胆固醇升高，糖尿病，高血压，同型半胱氨酸， 久坐的生活方式很重要，但这种疾病或其治疗似乎 成为最重要的。然而，在实践中对风险因素的修改是 远不理想，最重要的是，没有证据表明治疗这些 在结果之后，因素会更积极地发挥作用。 我们建议进行可行性研究，以确定招聘比率和成本。 积极风险因素管理与一般风险因素的随机对照试验 管理在一级和二级预防中的加速 系统性红斑狼疮的动脉粥样硬化。大型随机对照试验 一种积极的动脉粥样硬化血管疾病治疗策略的试验 针对使用B复合维生素的一级预防，普伐他汀是一种新的 女性系统性红斑狼疮的电话危险因素管理系统。

DESCRIPTION (Taken from the application): Systemic Lupus Erythematosus (SLE) affects over 200,000 Americans. It has been known for over 20 years that patients with SLE are at increased risk for accelerated atherosclerosis. Known risk factors (smoking, obesity, family history of CAD, elevated cholesterol, diabetes, hypertension, homocysteine, sedentary life style are important but the disease or its treatment appears to be the most important of all. Risk factor modification in practice, however, is far from ideal and, most importantly there is no evidence that treating these factors more aggressively would after outcome. We propose a feasibility study to determine recruitment rate and costs of a randomized trial of aggressive risk factor management versus usual risk factor management in the primary and secondary prevention of accelerated atherosclerosis of system lupus erythematosus. The large randomized controlled trial of an aggressive atherosclerosis vascular disease modifying strategy is aimed at primary prevention using B complex vitamins, Pravastatin, an a novel telephone risk factor management system in women with SLE.